TD Cowen lowered its price target for AnaptysBio, and Scotiabank downgraded the stock to hold.
2 reports, 2 independent
Updated Oct 21
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen lowered its price target for AnaptysBio, and Scotiabank downgraded the stock to hold.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.TD Cowen lowered its price target, and Cantor Fitzgerald reissued a rating on AnaptysBio.1 source
TD Cowen and Scotiabank issued new ratings and price targets for AnaptysBio.1 source
Keep exploring
The entities involved
-
TD Cowen
American investment bank
-
Scotiabank
Canadian bank based in Toronto
Related events
- TD Cowen and Bank of America issued buy ratings and increased price targets on November 2, 2026.
- TD Cowen and Scotiabank provided ratings and price targets for Devon Energy.
- TD Cowen decreased its target price for CACI on October 24, 2026.
- Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.
- TD Cowen raised its price target for HCA Healthcare, Inc. on October 23, 2026.